Lymph Node Metastasis, Pancreatic Adenocarcinoma
Conditions
Brief summary
Aim of the study will be to investigate if Endoscopic Ultrasound (EUS) with elastography can be purposed between the routine staging examinations in patients with pancreatic adenocarcinoma without distant metastasis for the staging of lymph nodes status (N in TNM classification) * in RESECTABLE pancreatic cancer the investigators will evaluate the concordance with EUS elastography and histological findings of lymph nodes obtained during surgery, in order to assess the sensibility, specificity and the positive and negative predictive value of EUS with elastography, the disease-free survival, the percentage of metastatic patients and the overall survival (in patients with or without metastatic lymph nodes). * in BORDERLINE resectable and UNRESECTABLE non-metastatic (advanced locally) disease, the investigators will evaluate if the malignant lymph nodes samples during EUS with elastography and fine needle aspiration (FNA) will be related to a decreased survival. Secondary aim will be to register the prognosis (in terms of survival) of the patients with para-aortic and mediastinal pathological lymph nodes (related to a decreases survival in some series in literature)
Detailed description
Pathological lymph nodes will be assessed by EUS with elastography as lymph nodes: hypoechoic, rounded, rigid (blue) and big (bigger than 1 centimeter)
Interventions
observational study
Sponsors
Study design
Eligibility
Inclusion criteria
pancreatic adenocarcinoma without distant metastasis; patients \> 18 years
Exclusion criteria
distant metastasis and pancreatic adenocarcinoma
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CONCORDANCE (PERCENTAGE) of pathological lymph nodes at EUS with elastography and surgical pathology report | 2 years | resectable pancreatic cancer |
| OVERALL SURVIVAL (MONTHS) in metastatic lymph node presence | 2 years | resectable pancreatic cancer |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| OVERALL SURVIVAL (MONTHS) | 2 years | para-aortic and mediasitnum metastatic lymph nodes presence |
Countries
Italy